

PERSONAL INFORMATION



Name ANTONINO, BRUNO (CF: BRNNNN82C28L682P)
Address 98, VIA VARESINA, 20151, MILANO, ITALY
Telephone +39 345 4550642
Personal E-mail 82antonino.bruno@gmail.com

Nationality Italian

Date of birth March 29th, 1982

EDUCATION AND TRAINING

• **Dates (from – to)** 2021-2030
• **Name and type of organization providing education and training** Ministry of Education, Universities and Research
• **Principal subjects/occupational skills covered** General pathology, immunology, clinical pathology
• **Title of qualification awarded** National Scientific Qualification (Abilitazione Scientifica Nazionale-ASN), II fascia, General and Clinical Pathology (06/A2 - MED/04).

• **Dates (from – to)** 2008-2011
• **Name and type of organization providing education and training** University of Insubria (Varese) and IRCCS MultiMedica (Milan).
• **Principal subjects/occupational skills covered** Functional and phenotype characterization of tumor infiltrating inflammatory cells (macrophages, neutrophils, NKs) by flow cytometry and cell sorting, biochemistry, and molecular biology.
Title of PhD thesis: *“The NK cells phenotype and function in resected Non-Small Cell Lung Cancer: differences between squamous and adenocarcinoma and relation to tumor angiogenesis”*.
• **Title of qualification awarded** PhD in Cellular and Molecular Biology.

• **Dates (from – to)** 2006-2007
• **Name and type of organization providing education and training** Master's Degree in Veterinarian Biotechnologies, University of Milan.

<ul style="list-style-type: none"> •Principal subjects/occupational skills covered 	<p>Chemistry, Math, Physic, Biology, Molecular Biology, Molecular Genetic, Biochemistry, Cellular Biochemistry, Immunology, Microbiology, Molecular Virology, Anatomy, Physiology, Pharmacology and Toxicology, Pathology, Parasitology, Molecular Pathology, and Immunology.</p> <p>Title of graduation thesis: “<i>Frequency analysis of genes encoding for 3 leukocidins (PVL, LukM, LukD-E) in S. Aureus strains isolated from cows with subclinical mastitis</i>”.</p>
<ul style="list-style-type: none"> • Title of qualification awarded 	<p>Graduated (110 cum laude).</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and type of organization providing education and training •Principal subjects/occupational skills covered 	<p>2002-2006</p> <p>Bachelor’s Degree in biotechnologies, University of Milan.</p> <p>Chemistry, Math, Physic, Biology, Molecular Biology, Molecular Genetic, Biochemistry, Cellular Biochemistry, Immunology, Microbiology, Molecular Virology, Anatomy, Physiology, Pharmacology and Toxicology, Pathology, Parasitology, Molecular Pathology and Immunology.</p> <p>Title of graduation thesis: “<i>Production of ROL Lipase using Pichia pastoris expression system</i>”.</p> <p>I carried out this experimental thesis at the Chemical Engineer Department, Universidad Autonoma de Barcelona, Barcelona, under supervision of Prof. Pau Ferrer and Dr. Ramon Ramon (ERASMUS project).</p>
<ul style="list-style-type: none"> • Title of qualification awarded 	<p>Graduated (104/110).</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and type of organization providing education and training •Principal subjects/occupational skills covered • Title of qualification awarded 	<p>1996-2001</p> <p>“E. Cairoli” Classic Secondary School, Varese.</p> <p>Italian, Italian Literature, Latin, Greek, Latin and Greek Literature, English, English Literature, Science, Math, Physics, Philosophy.</p> <p>Upper school leaving certificate (marks 67/100).</p>

WORKING EXPERIENCES

- **Dates (from – to)** March 2022-to date
- **Name and address of employer** Laboratory of Immunology and General Pathology, University of Insubria, Varese, Italy
- **Type of business or sector** Tumor immunology, inflammation, angiogenesis.
- **Occupation or position held** Assistant Professor of pathology and immunology (RTD-B), S.S.D. MED/04 Patologia generale ,S.C. 06/A2.

- **Dates (from – to)** September 2021-December 2021
- **Name and address of employer** Biomedical Sciences, University of Insubria, Varese, Italy.
- **Type of business or sector** General Pathology, Physiopathology, and Immunology.
- **Occupation or position held** Assistant Professor (RTD-B)

- **Dates (from – to)** June 2021-to date
- **Name and address of employer** Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry, and Immunology, IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST).
- **Type of business or sector** Tumor immunology, inflammation, angiogenesis.
- **Occupation or position held** Principal Investigator/Group Leader, head of Laboratory of Innate Immunity, coordinating a research group with 1 postdoc, 2 PhD students, 1 lab. technician and 1 MSc student.

- **Dates (from – to)** September 2021-December 2021
- **Name and address of employer** Biomedical Sciences, University of Insubria, Varese, Italy.
- **Type of business or sector** General Pathology, Pathophysiology, and Immunology.
- **Occupation or position held** Contract Professor, cdl in Pathology.

- **Dates (from – to)** January 2020-May 2021
- **Name and address of employer** Unit of Molecular Pathology, Biochemistry, and Immunology, IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST).
- **Type of business or sector** Tumor immunology, inflammation, angiogenesis.
- **Occupation or position held** Principal Investigator/Group Leader (permanent staff).

- **Dates (from – to)** June 2017- December 2019
- **Name and address of employer** Laboratory of Vascular Biology and Angiogenesis, IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST).
- **Type of business or sector** Tumor immunology, inflammation, angiogenesis.
- **Occupation or position held** Senior researcher (permanent staff).

- **Dates (from – to)** Mach 2016- May 2017
- **Name and address of employer** Laboratory of Vascular Biology and Angiogenesis, IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST), funded by Fondazione Umberto Veronesi.
- **Type of business or sector** Molecular and Cellular Biology applied to Oncology.
- **Occupation or position held** Post-doc.
- **Main activities and responsibilities** Cancer related inflammation, tumor immunology, tumor angiogenesis. Cancer chemoprevention and angioprevention.

- **Dates (from – to)** November 2014- Current
- **Name and address of employer** University of Milan, Milan, Italy.
- **Type of business or sector** Pharmacology (Master's in Pharmacology and Oncology).
- **Occupation or position held** Contract professor.
- **Main activities and responsibilities** Training of master students in the field of tumour microenvironment and tumour angiogenesis as targets for therapy and prevention.

- **Dates (from – to)** July 2015- March 2016
- **Name and address of employer** Laboratory of Experimental Surgery, department of Biotechnologies and Life Sciences, Varese and IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST).
- **Type of business or sector** Molecular and Cellular Biology applied to Oncology.
- **Occupation or position held** Post-doc.
- **Main activities and responsibilities** Evaluation of tumor exosome contribution in shaping natural killer cell response. Isolation of exosomes from tumor cell lines and clinical samples (serum, plasma). Polarization of immune cells with exosomes for phenotype and functional characterization.

- **Dates (from – to)** January 2015- June 2015
- **Name and address of employer** IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST).
- **Type of business or sector** Cancer related inflammation, tumor immunology, tumor angiogenesis.
- **Occupation or position held** Senior researcher.
- **Main activities and responsibilities** Functional and phenotypic characterization of tumor infiltrating lymphocytes and crosstalk with tumor microenvironment. Anti-angiogenic activity of metformin/phenformin and phytochemicals *in vitro* and *in vivo*. Evaluation of cardiovascular toxicity of antineoplastic drugs *in vitro* and *in vivo*. Evaluation of the systemic distribution of nanoparticles and toxic effects *in vivo*.

<ul style="list-style-type: none"> • Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities 	<p>December 2011- December 2014</p> <p>IRCCS MultiMedica, Milano, Scientific and Technologic Pole (PST)-</p> <p>Cancer related inflammation, tumor immunology, tumor angiogenesis. 3 years FIRC Fellowship (Postdoctoral). Isolation and characterization of Cancer Stem Cells (CSCs) from MCF7, MDA-MB-213, HT-29, HCT-116, DAOY, ONS-76 cell lines and from clinical samples (breast and colon-rectal cancer). Evaluation of phytochemical ability to pre-sensitize CSCs to anti neoplastic drugs. Functional and phenotype characterization of tumor infiltrating lymphocytes and crosstalk with tumour microenvironment. Anti-angiogenic activity of metformin/phenformin and phytochemicals <i>in vitro</i> and <i>in vivo</i>.</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities 	<p>October 2008- December 2011</p> <p>IRCCS MultiMedica Milano, Scientific and Technologic Pole.</p> <p>Cancer related inflammation, tumor immunology, tumor angiogenesis. PhD student</p> <p>1) Phenotypic and functional characterization of tumor infiltrating NKs in solid cancers (NSCLC, colorectal, renal, breast) and relation with tumor angiogenesis. 2) <i>In vitro</i> and <i>in vivo</i> evaluation of anti-angiogenic activity by phytochemicals. 3) <i>In vitro</i> and <i>in vivo</i> toxicity exerted by nanoparticles and nanomaterials: roles in inflammation and angiogenesis. 5) Gene profile analysis on aged endothelial cells to identify novel targets for anti-angiogenic therapy.</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities 	<p>March 2008- October 2008</p> <p>Università degli Studi di Milano Bicocca, department of Biotechnologies and Biosciences.</p> <p>Molecular and Cellular Biology. Pre-doctoral fellow.</p> <p>Evaluation of mRNAs processing machinery, focusing on alternative splicing and related alterations in SLA.</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities 	<p>September 2007- December 2007</p> <p>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Department of Neuroscience, Laboratory of Psychopharmacology.</p> <p>Psychopharmacology. Junior Fellow.</p> <p>“Drug craving” e “relapse” studies for abuse substances (cocaine, nicotine, and ethanol) in murine models.</p>
<ul style="list-style-type: none"> • Dates (from – to) • Name and address of employer • Type of business or sector 	<p>September 2006- September 2007</p> <p>Università degli Studi di Milano, Department of Animal Pathology.</p> <p>Pathology-Microbiology, Infectious Diseases.</p>

• Occupation or position held	Internship.
• Main activities and responsibilities	Molecular profiling for the distribution of genes encoding for leucocidins (pvl, LukM, LukD-E) in 1 <i>S. Aureus</i> strains (milk, skin), derived from cows with clinical and sub-clinical mastitis.
• Dates (from – to)	February 2006- September 2006
• Name and address of employer	Department of Chemical Engineer, Universidad Autonoma de Barcelona, Laboratory of Chemical Engineer.
• Type of business or sector	Biochemistry, Molecular Biology, Chemical Engineer.
• Occupation or position held	Internship.
• Main activities and responsibilities	Production of recombinant proteins in <i>E. coli</i> and <i>P. pastoris</i>

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

	ENGLISH
• Reading skills	Excellent
• Writing skills	Excellent
• Verbal skills	Fluent
	SPANISH
• Reading skills	Excellent
• Writing skills	Excellent
• Verbal skills	Fluent

TECHNICAL SKILLS AND COMPETENCIES

Informatic/Biostatistic skills:

Windows and Mac OS; Windows Office suite (Word, Excel, Power Point), Internet Explorer and Outlook Express, Graph Pad Prism, Adobe Photoshop, ImageJ, Gimp, EndNote, FACS Diva, Flow-Logic, MeV. Data analysis, statistical analysis, sample size determination for pre-clinical and clinical studies.

Bioinformatic skills:

Use of common databases (NCBI, EBI).

Laboratory techniques:

DNA-RNA extraction and purification, PCR, RT-PCR, qPCR.

Molecular Cloning, bacterial transformation, production of recombinant proteins in *E. coli* and *P. pastoris*.

Primary cell cultures and maintenance: tumour cells isolation (breast, lung, colon), macrophages, neutrophils, Natural Killer cells.

Cell line culture and maintenance.

Cancer stem cells isolation and maintenance from cell lines and clinical samples.

Immune-magnetic cell sorting with commercial kits (columns and tube beads).

Multicolor flow cytometry (FC, up to 20 colors), FC for immune cell subset identification and cytokine profiling (intracellular staining), FC for AnnexinV and 7-AAD expression (Apoptosis), cell cycle (PI, Dapi) and ROS production (DH₂DCF-DA, mitosox, cellRox).

Multicolor panel design for flow cytometry and complex flow data analysis.

Isolation and characterization of tumour-derived exosomes and extracellular vesicles from cell lines and their characterization by flow cytometry.

In vitro angiogenesis assay: endothelial cell morphogenesis on matrigel, wound-healing assay, chemotaxis and chemoivasion on Boyden Chambers and trans wells, scratch-assay, sprouting assay.

Animal models handling and care: mice, rats, zebrafish, xenopus.

In vivo angiogenesis assay: matrigel sponge assay.

In vivo expertise: organ isolation, tumour xenograft on different mouse strains, cell, and drugs injection (s.c., i.v, i.p., p.t.,)

Related skills:

Writing of Clinical Protocols for Ethics Committee; Management of informed consent. Freelance medical writer.

Management of a flow cytometry facility (BD FACS Canto II, BD FACS Fortessa x20, BD FACS ARIA II-cell sorter).

Management of a zebrafish facility: animal breeding, preparation of technical documentations, organization of site visits. Interaction with clinicians and nurses to define inclusion/exclusion criteria of patients, their classification according to clinical parameters

Grant writing for research funding (AIRC, Cariplo, Ricerca Finalizzata, AICR, H2020). Preparation of budgets, middle and final reports for funded projects. Co-reviewer for ERC grants (panel LS4) and AACR fellowships.

Totally independent in manuscript, review, case report, commentary, and grant proposal writing.

Book chapters and proceeding writing, aimed at both scientific and not-scientific audience.

Laboratory management (instrumentations, personnel coordination, and training).

Tutorship and mentorship for undergraduate students, PhD students, post-docs.

Dissemination of results to lay public (blogs, social networks, newspapers, radio, TV).

Experience as mentor:

2019-current: PhD supervisor for Dr. Matteo Gallazzi, PhD in Biotechnologies and Life Sciences, XXXV cycle, University of Insubria, Varese, Italy. Dr. Gallazzi is currently a PhD student in my Lab, working on a project aimed at investigating the contribution of Natural Killer cells in prostate cancer progression and angiogenesis. He's also recipient of funds from the MOH (Ricerca Finalizzata Giovani Ricercatori, 90k euro-3 years) as collaborator.

2019-2020: MSc thesis tutor for Martina Cucchiara, CdL in Medical Biotechnologies, University of Milan Bicocca, Milan, Italy. Martina is currently a pre-doctoral fellow in my Lab, working on a project

investigating the contribution of NK cells in pancreatic cancer progression and fibrosis.

2018-2019: MSc supervisor for Dr. Matteo Gallazzi, CdL in Biomedical Sciences, University of Insubria, Varese, Italy. Dr. Gallazzi was involved in a project aimed at investigating the contribution of Natural Killer cells in prostate cancer progression and angiogenesis.

2013-2016: PhD supervisor for Dr. Barbara Bassani, PhD in Biotechnologies, Biosciences and Surgery, XXIX cycle, University of Insubria, Varese, Italy. Dr. Bassani was involved in a project investigating the contribution of NK cells in colorectal cancer progression and angiogenesis. Dr. Bassani is currently a post-doctoral fellow at National Cancer Institute (Group of Prof. Mario Paolo Colombo), Milan, Italy.

2010-2011: BSc thesis supervisor for Dr. Martina de Bernardi. Martina was involved in a project investigating the contribution of NK cells in colorectal cancer progression and angiogenesis.

2009-2010: Dr. Michela Guerini Rocco, BSc thesis (project on NK cell in colorectal cancer). Michela was involved in a project investigating the contribution of NK cells in lung cancer progression and angiogenesis.

ADDITIONAL INFORMATION

Grants

Past/active:

1. *"Tumor-infiltrating/tumor associated natural killer cells in prostate cancer progression and angiogenesis"*. Funding agency: Italian Association for cancer Research (AIRC), MFAG-22818. Project duration: 2020-2024. Budget: 498.000 euros. Role in the project: PI.

2. *"Pancreatic ductal adenocarcinoma microenvironment: interplay between fibrosis and NK cells"*. Funding agency: Fondazione Cariplo. Project duration: 2020-2022. Budget: 80.000 euros. Role in the project: Partner.

3. *"Phenotype and functional characterization of peripheral blood NK cells in patients with symptomatic atherosclerosis"*. Funding agency: Institutional funds. Project duration: October-2019-october 2020. Budget: 12.000 euros. Role in the project: Co-PI.

4. *"Verso un rene in provetta"*. Funding agency: Bicocca Crowd funding. Budget: 6.735 euros. Role in the project: Partner.

5. *"Cardio-protective activities of a polyphenol-rich extracts from olive-mill wastewaters"*. Funding agency: Donation. Project duration: 2018-2019. Budget: 30.000 euros. Role in the project: Co-PI.

6. *"Effects of ultra-purified polyphenol-rich olive mill wastewater extracts on tumour cells (prostate and lung cancer): molecular pathways involved"*. Funding agency: Donation. Project duration: 2018-2019. Budget: 30.000 euros. Role in the project: Co-PI.

Memberships

EACR, AACR, SIC, SIICA regular member

From 2018: Member of the board of directors, Italian Society of Cancerology (SIC)

Reviewer for:

Bio-protocols, Cancers, Carcinogenesis, Cells, Clinical and Experimental Metastasis, Experimental Dermatology, Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Frontiers in Immunology, International Journal of Cancer, International Journal of Molecular Science, Journal of the National Cancer Institute, Journal of Immunology Research, Vaccines, PlosOne

Publications

H-index: 23 (Scopus),

<https://www.scopus.com/affil/profile.uri?id=60104444&origin=AuthorResultsList>

1. La Sala L, Gandini S, **Bruno A**, Allevi R, Gallazzi M, Senesi P, Palano MT, Meregalli P, Longhi E, Sommesse C, Luzi L, Trabucchi E. SARS-CoV-2 Immunization Orchestrates the Amplification of IFN γ -Producing T Cell and NK Cell Persistence. Front Immunol. 2022 Feb 14;13:798813. doi: 10.3389/fimmu.2022.798813. PMID: 35237261; PMCID: PMC8882867.
2. Maria Teresa Palano, Martina Cucchiara, Matteo Gallazzi, Lorenzo Mortara, Gian Franco Gensini, Gaia Spinetti*, Giuseppe Ambrosio*, **Antonino Bruno***. When a friend becomes your enemy: Natural Killer cells in atherosclerosis and atherosclerosis-associated risk factors. Front Immunol. 2022 Jan 13;12:798155. doi: 10.3389/fimmu.2021.798155.
3. Maria Teresa Palano, Matteo Gallazzi, Martina Cucchiara, Andrea De Lerma Barbaro, Daniela Gallo, Barbara Bassani, **Antonino Bruno***, Lorenzo Mortara*. Neutrophils and natural killer cell interaction in cancers: dangerous liaisons instructing immunosuppression and angiogenesis. Vaccines (Basel). 2021 Dec 16;9(12):1488. doi: 10.3390/vaccines9121488.
4. Maurizia Mello-Grand*, **Antonino Bruno***, Lidia Sacchetto, Simone Cristoni, Ilaria Gregnanin, Paolo Gontero, Caterina Peraldo-Neia, Douglas Mc Clain Noonan, Adriana Albini and Giovanna Chiorino. Two novel ceramide-like molecules and miR-5100 levels as biomarkers improve prediction of prostate cancer in grey-zone PSA. Front Oncol. 2021 Nov 19;11:769158. doi: 10.3389/fonc.2021.769158. eCollection 2021.
5. Andrea De Lerma Barbaro, Maria Teresa Palano, Martina Cucchiara, Matteo Gallazzi, Lorenzo Mortara, **Antonino Bruno***. Metabolic rewiring in the tumor microenvironment to support immunotherapy: a focus on neutrophils, polymorphonuclear MDSCs and NK cells. Vaccines, *in press*.

6. Albini A, Calabrone L, Carlini V, Benedetto N, Lombardo M, **Bruno A**, Noonan DM. Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis. *Front Immunol*. 2021 Sep 27;12:718136. doi: 10.3389/fimmu.2021.718136.
7. Albini A, Gallazzi M, Palano MT, Carlini V, Ricotta R, **Bruno A**, Stetler-Stevenson WG, Noonan DM. TIMP1 and TIMP2 Downregulate TGF β Induced Decidual-like Phenotype in Natural Killer Cells. *Cancers (Basel)*. 2021 Oct 1;13(19):4955. doi: 10.3390/cancers13194955. PMID: 34638439 Free PMC article.
8. Salvini M, Maggi F, Damonte C, Mortara L, **Bruno A**, Mora B, Brociner M, Mattarucchi R, Ingrassia A, Sirocchi D, Bianchi B, Agnoli S, Gallazzi M, Merli M, Ferrario A, Bombelli R, Barraco D, Baj A, Bertù L, Grossi PA, Passamonti F. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation. *Bone Marrow Transplant*. 2021 Oct 11:1-3. doi: 10.1038/s41409-021-01487-4.
9. Adriana Albini, Marco Mario Giacomo Festa, Nadja Ring, Denisa Baci, Michael Rehman, Giovanna Finzi, Fausto Sessa, Serena Zacchigna, **Antonino Bruno***, Douglas M Noonan*, A polyphenol-rich extract of Olive Mill Wastewater Enhances cancer chemotherapy effects, while mitigating cardiac toxicity. *Front. Pharmacol.*, 03 August 2021 | <https://doi.org/10.3389/fphar.2021.694762>
10. Bianchi F, Dama E, Di Nicolantonio F, Baldassarre G, Guerriero I, Torchiano E, **Bruno A**, Blandino G, Allavena P, Chiarugi P, Sozzi G, D'Incalci M, Normanno N. COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). *ESMO Open*. 2021 Jun;6(3):100165. doi: 10.1016/j.esmoop.2021.100165.
11. Matteo Gallazzi, Denisa Baci, Lorenzo Mortara, Annalisa Bosi, Giuseppe Buono, Angelo Naselli, Andrea Guarneri, Federico Dehò, Paolo Capogrosso, Adriana Albini, Douglas Mc Clain Noonan, **Antonino Bruno**. Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production, and secrete monocyte-recruiting and polarizing factors. *Front Immunol*. 2021 Jan 25;11:586126. doi: 10.3389/fimmu.2020.586126.
12. Sansone C, **Bruno A**, Piscitelli C, Baci D, Fontana A, Brunet C, Noonan DM, Albini A. Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy. *Cells*. 2021 Jan 25;10(2):231. doi: 10.3390/cells10020231.
13. Sansone C, Galasso C, Lo Martire M, Fernández TV, Musco L, Dell'Anno A, **Bruno A**, Noonan DM, Albini A, Brunet C. In Vitro Evaluation of Antioxidant Potential of the Invasive Seagrass *Halophila stipulacea*. *Mar Drugs*. 2021 Jan 16;19(1):37. doi: 10.3390/md19010037.

14. Festa M, Sansone C, Brunet C, Crocetta F, Di Paola L, Lombardo M, **Bruno A**, Noonan DM, Albini A. Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. *Int J Mol Sci.* 2020 Nov 7;21(21):8364. doi: 10.3390/ijms21218364.
15. Baci D, Bosi A, Parisi L, Buono G, Mortara L, Ambrosio G, **Bruno A**. Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis. *Int J Mol Sci.* 2020 Sep 28;21(19):E7165. doi: 10.3390/ijms21197165
16. Denisa Baci, Maila Chirivi, Valentina Pace, Fabio Maiullari, Marika Milan, Andrea Rampin, Paolo Somma, Dario Presutti, Silvia Garavelli, **Antonino Bruno**, Stefano Cannata, Chiara Lanzuolo, Cesare Gargioli, Roberto Rizzi, Claudia Bearzi. Extracellular vesicles from skeletal muscle cells efficiently promote myogenesis in induced pluripotent stem cells. *Cells.* 2020 Jun 23;9(6):E1527. doi: 10.3390/cells9061527.
17. Daniela Gallo, Eliana Piantanida, Matteo Gallazzi, Luigi Bartalena, Maria Laura Tanda, **Antonino Bruno** and Lorenzo Mortara. Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher. *Front Endocrinol (Lausanne).* 2020 Jul 17;11:406. doi: 10.3389/fendo.2020.00406.
18. Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A*, **Bruno A***, Mortara L*. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. *Int J Mol Sci.* 2020 Apr 28;21(9). pii: E3125. doi: 10.3390/ijms21093125.
19. Denisa Baci*, **Antonino Bruno***, Caterina Cascini, Matteo Gallazzi; Lorenzo Mortara, Fausto Sessa, Giuseppe Pelosi, Adriana Albini, Douglas M. Noonan. CXCR4/CXCL12, CCL2, TNF- α and MMP-9, growth, invasion and pro-angiogenic properties are downregulated in prostate cancer cells by Acetyl- L-carnitine, a potential prevention and interception agent. *J Exp Clin Cancer Res.* 2019 Nov 12;38(1):464. doi: 10.1186/s13046-019-1461-z.
20. Galasso C, Gentile A, Orefice I, Ianora A, **Bruno A**, Noonan DM, Sansone C, Albini A, Brunet C. Microalgal Derivatives as Potential Nutraceutical and Food Supplements for Human Health: A Focus on Cancer Prevention and Interception. *Nutrients.* 2019 May 29;11(6). pii: E1226. doi:10.3390/nu11061226.
21. **Antonino Bruno**, Lorenzo Mortara, Denisa Baci, Douglas Noonan, Adriana Albini. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. *Front. Immunol.*, 18 April 2019. <https://doi.org/10.3389/fimmu.2019.00771>.
22. Bassani B, Baci D, Gallazzi M, Poggi A, **Bruno A***, Mortara L*. Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects. *Cancers (Basel).* 2019 Apr 1;11(4). pii: E461. doi: 10.3390/cancers11040461.

23. Denisa Baci, Matteo Gallazzi, Caterina Cascini, Matilde Tramacere, Daniela De Stefano, **Antonino Bruno**[@], Douglas M. Noonan, Adriana Albini, Downregulation of Pro-Inflammatory and Pro-Angiogenic Pathways in Prostate Cancer Cells by a Polyphenol-Rich Extract from Olive Mill Wastewater. *Int J Mol Sci*. 2019 Jan 14;20(2), doi: 10.3390/ijms20020307.
24. Matteo Fanuli, Mirko Battaglia, Marco Tremolati, **Antonino Bruno**[@], Luca Parisi, Giampietro Farronato, Dental sealants: use of hydrophilic materials in clinical practice and professional training, *BMC Oral Health, Dent J (Basel)*. 2018 Oct 1;6(4). pii: E52. doi: 10.3390/dj6040052.
25. Lorenzo Mortara, Enrica Balza, **Antonino Bruno**, Alessandro Poggi, Paola Orecchia, Barbara Carnemolla, Anti-cancer therapies employing il-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy, *Front Immunol*. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905.
26. **Bruno A**^{*}, Bassani B^{*}, D'Urso DG, Pitaku I, Cassinotti E, Pelosi G, Boni L, Dominioni L, Noonan DM, Mortara L, Albini A. Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer. *FASEB J*. 2018 May 15:fj201701103R. doi:10.1096/fj.201701103R.
27. Annalisa Bosi, Silvia Zanellato, Barbara Bassani, Andriana Albini, Alessandra Musco, Maria Cattoni, Matteo Desio, Elisa Nardecchia, Davide Giuseppe D'Urso, Andrea Imperatori, Lorenzo Dominioni, Douglas Noonan, Lorenzo Mortara, and **Antonino Bruno**. Natural Killer cells from malignant pleural effusion are endowed with a decidual-like pro-angiogenic polarization, *J Immunol Res*. 2018 Mar 29;2018:2438598. doi: 10.1155/2018/2438598.
28. Baci D, **Bruno A**, Bassani B, Tramacere M, Mortara L, Albini A, Noonan DM. Acetyl-L-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways. *Cancer Lett*. 2018 Aug 10;429:100-116. doi: 10.1016/j.canlet.2018.04.018.
29. Albini A^{*}, **Bruno A**^{*}, Noonan DM, Mortara L. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. *Front Immunol*. 2018 Apr 5;9:527. doi: 10.3389/fimmu.2018.00527
30. Albini A, **Bruno A**, Bassani B, D'Ambrosio G, Pelosi G, Consonni P, Castellani L, Conti M, Cristoni S, Noonan DM. Serum Steroid Ratio Profiles in Prostate Cancer: A New Diagnostic Tool Toward a Personalized Medicine Approach. *Front Endocrinol (Lausanne)*. 2018 Apr 5;9:110. doi: 10.3389/fendo.2018.00110.
31. Luca Parisi, Elisabetta Gini, Denisa Baci, Marco Tremolati, Matteo Fanuli, Barbara Bassani, Giampietro Farronato, **Antonino Bruno**^{*} and Lorenzo Mortara^{*}, Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders? *J Immunol Res*. 2018 Jan 14;2018:8917804. doi: 10.1155/2018/8917804.

32. Albini A, Bassani B, Baci D, Dallaglio K, Gallazzi M, Corradino P, **Bruno A***, Noonan DM*. Nutraceuticals and "repurposed" drugs of phytochemical origin in prevention and interception of chronic degenerative disease and cancer, *Curr Med Chem*. 2017 Sep 20. doi: 10.2174/0929867324666170920144130.
33. E. Nuti, B. Bassani, C. Camodeca, L. Rosalia, A. Cantelmo, C. Gallo, D. Baci, **A. Bruno**, E. Orlandini, S. Nencetti, D. Noonan, A. Albini, A. Rossello, Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues, *European Journal of Medicinal Chemistry* (2017), doi: 10.1016/j.ejmech.2017.07.024.
34. Parisi L, Bassani B, Tremolati M, Gini E, Farronato G, **Bruno A**. Natural Killer Cells in the Orchestration of Chronic Inflammatory Diseases. *J Immunol Res*. 2017;2017:4218254. doi: 10.1155/2017/4218254.
35. Simone Cristoni, Guglielmo Dusi, Paolo Brambilla, Adriana Albini, Matteo Conti, Maura Brambilla, **Antonino Bruno**, Francesca Digaudio, Luca Ferlin, Valeria Tazzari, Silvia Mengozzi, Simone Barera, Carlos Salier, Luigi Rossi Bernardi, and Douglas M. Noonan, SANIST: optimization of a technology for compound identification based on the European Union directive with applications in forensic, pharmaceutical and food analyses, *J Mass Spectrom*. 2016 Oct 24. doi: 10.1002/jms.3895.
36. Barbara Bassani, Teresa Rossi, Daniela De Stefano, Daniele Pizzichini, Paola Corradino, Nicoletta Macrì, Douglas M. Noonan, Adriana Albini*, **Antonino Bruno***, Potential chemopreventive activities of a polyphenol rich purified extract from olive mill wastewater on colon cancer cells, *Journal of Functional Foods* 7 (2016) 236–248, <http://dx.doi.org/10.1016/j.jff.2016.09.009>.
37. Cristina Gallo, Katiuscia Dallaglio, Barbara Bassani, Teresa Rossi, Armando Rossello, Douglas Noonan, Gabriele D'Uva , **Antonino Bruno**, Adriana Albini, Hop derived flavonoid Xanthohumol inhibits endothelial cell functions via AMPK activation, *Oncotarget*. 2016 Sep 13;7(37):59917-59931. doi: 10.18632/oncotarget.10990.
38. Elisa Principi*, Rossana Girardello*, **Antonino Bruno***, Isabella Manni, Elisabetta Gini, Arianna Pagani, Annalisa Grimaldi, Federico Ivaldi, Terenzio Congiu, Daniela De Stefano, Giulia Piaggio, Magda de Eguileor, Douglas M. Noonan and Adriana Albini. Systemic distribution of single-walled carbon nanotubes in a novel model: alteration of biochemical parameters, metabolic functions, liver accumulation, and inflammation in vivo. *Int J Nanomedicine*. 2016 Sep 1;11:4299-316. doi: 10.2147/IJN.S109950.
39. Barbara Bassani, Desirée Bartolini, Arianna Pagani, Elisa Principi, Massimo Zollo, Douglas Noonan, Adriana Albini, **Antonino Bruno**, Fenretinide (4-HPR) targets caspase-9, ERK 1/2 and the Wnt3a/b-catenin pathway in medulloblastoma cells and medulloblastoma cell spheroids, *PLoS One*. 2016 Jul1;11(7):e0154111. doi: 10.1371/journal.pone.0154111.
40. Adriana Albini, Francesco Bertolini, Barbara Bassani, **Antonino Bruno**, Cristina Gallo, Stefano Caraffi, Sally Maramotti,

Douglas M. Noonan, Biomarkers of cancer angioprevention for clinical studies, *Ecancermedicalscience*. 2015 Nov 24;9:600. doi: 10.3332/ecancer.2015.600.

41. Adriana Albini*, **Antonino Bruno***, Cristina Gallo, Giorgio Pajardi, Douglas M. Noonan, Katiuscia Dallaglio, Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity, *Connect Tissue Res*. 2015;56(5):414-25. doi: 10.3109/03008207.2015.1066780.

42. Adriana Albini, Daniela Briga, Matteo Conti, **Antonino Bruno**, Daniela Farioli, Sara Canali, Ilaria Sogno, Gioacchino D' Ambrosio, Paolo Consonni, Douglas M. Noonan, SANIST: a rapid mass spectrometric SACI/ESI data acquisition and elaboration platform for verifying potential candidate biomarkers, *Rapid Commun Mass Spectrom*. 2015 Oct 15;29(19):1703-10. doi: 10.1002/rcm.7270.

43. Adriana Albini, Arianna Pagani, Laura Pulze, **Antonino Bruno**, Elisa Principi, Terenzio Congiu, Elisabetta Gini, Annalisa Grimaldi, Barbara Bassani, Silvio De Flora, Magda de Eguileor, Douglas M Noonan, Environmental impact of multi-wall carbon nanotubes in a rodent model of exposure: systemic distribution, macrophage accumulation and amyloid deposition, *Int J Nanomedicine*. 2015 Sep 29;10:6133-45. doi: 10.2147/IJN.S85275.

44. Nuti Elisa, Cantelmo, Anna Rita Gallo Cristina, **Bruno Antonino**, Bassani Barbara, Camodeca Caterina, Tuccinardi Tiziano, Vera Laura, Orlandini Elisabetta, Nencetti Susanna, Stura Enrico, Martinelli Adriano, Dive Vincent, Albini Adriana, Rossello Armando, N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in vivo Antiangiogenic Activity, *J Med Chem*. 2015 Sep 24;58(18):7224-40. doi: 10.1021/acs.jmedchem.5b00367.

45. Lorenzo Mortara, Silvia Zanellato, Barbara Bassani, Andrea Imperatori, Nicola Rotolo, Lorenzo Dominioni, Adriana Albini, Douglas M Noonan and **Antonino Bruno**, Polarization of Tumor Infiltrating Leukocytes from Innate Immunity and their role in the Pro-angiogenic Phenotype in NSCLC, *Journal of Clinical & Cellular Immunology*, doi: 10.4172/2155-9899.1000312.

46. Teresa Rossi, Barbara Bassani, Cristina Gallo, Sally Maramotti, Douglas M Noonan, Adriana Albini* and **Antonino Bruno***, Effect of a Purified Extract of Olive Mill Waste water on Endothelial Cell Proliferation, Apoptosis, Migration and Capillary-Like Structure in vitro and in vivo, *Journal of Bioanalysis & Biomedicine*, doi: 10.4172/1948-593X.S12-006.

47. Chiara Focaccetti*, **Antonino Bruno***, Elena Magnani, Desirée Bartolini, Elisa Principi, Katiuscia Dallaglio, Eraldo O. Bucci, Giovanna Finzi, Fausto Sessa, Douglas M. Noonan, Adriana Albini, Effects of 5-Fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. *PLoS One*. 2015 Feb 11;10(2):e0115686. doi: 10.1371/journal.pone.0115686.

48. Rossi T, Gallo C, Bassani B, Canali S, Albini A, **Bruno A**. Drink your prevention: beverages with cancer preventive

phytochemicals. *Pol Arch Med Wewn.* 2014 Dec 23;124(12):713-22.

49. Fania C, Sogno I, Vasso M, Torretta E, Leone R, **Bruno A**, Consonni P, Albini A, Gelfi C, A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification, *Clin Chim Acta.* 2014 Oct 11.pii: S0009-8981(14)00434-3.

50. **Antonino Bruno***, Guido Ferlazzo*, Adriana Albini, Douglas M Noonan, A think tank on TINK/TANKs: Tumor Infiltrating Natural Killer cells and their role in angiogenesis and tumor progression, *J Natl Cancer Inst.* 2014 Sep 1;106(8):dju200. doi: 10.1093/jnci/dju200.

51. **Bruno A@**, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan DM, Mortara L. Orchestration of angiogenesis by immune cells. *Front Oncol.* 2014 Jul 2;4:131. doi: 10.3389/fonc.2014.00131.

52. Kronska E, Fiori ME, Barbieri O, Astigiano S, Mirisola V, Killian PH, **Bruno A**, Pagani A, Rovera F, Pfeffer U, Sommerhoff CP, Noonan DM, Nerlich AG, Fontana L, Bachmeier BE. miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via downregulation of the inflammatory cytokines CXCL1 and -2. *Mol Oncol.* 2014 May;8(3):581-95. doi:10.1016/j.molonc.2014.01.005.

53. Dallaglio K, **Bruno A**, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, Calleri A, Bertolini F, Pfeffer U, Noonan DM, Albini A. Paradoxical effects of metformin on endothelial cells and angiogenesis. *Carcinogenesis.* 2014 May;35(5):1055-66. doi: 10.1093/carcin/bgu001.

54. **Bruno A***, Focaccetti C*, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, Cantelmo AR, Franzi F, Capella C, Ferlazzo G, Mortara L, Albini A, Noonan DM. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. *Neoplasia.* 2013 Feb;15(2):133-42.

Book chapters

1. Lorenzo Mortara, Denisa Baci, Grace Coco, Alessandro Poggi and **Antonino Bruno**. The dual role of natural killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies. Book: *Successes and Challenges of NK Immunotherapy* Chapter Number: 15. Elsevier, 10.1016/B978-0-12-824375-6.00014-X.

2. Bassani B., **Bruno A.**, Macrì N., Corradino P., Noonan D.M., Albini A. (2017) The Pharmacologist's Point of View: Mechanisms of Cardiotoxicity. In: Lestuzzi C., Oliva S., Ferrà F. (eds) *Manual of Cardio-oncology*. Springer, Cham, https://doi.org/10.1007/978-3-319-40236-9_7

3. **Bruno A**, Pagani A, Magnani E, Rossi T, Noonan DM, Cantelmo AR, Albini A. Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention.

Cancer Treat Res. 2014;159:401-26. doi: 10.1007/978-3-642-38007-5_23. PubMed PMID: 24114493.

4.Douglas M. Noonan, Agostina Ventura, **Antonino Bruno**, Arianna Pagani and Adriana Albini, The Angiogenic Switch: Role of Immune Cells, Immunologic Signatures of Rejection, 2011. https://doi.org/10.1007/978-1-4419-7219-4_5.

Academic achievements

1.Angiogenesi e angiogenesi infiammatoria come terapia e prevenzione in oncologia. Il modulo Master in Farmacia e Farmacologia Oncologica, Il modulo Perfezionamento Farmacia in OncologiaTerapie innovative in oncologia, March 24th 2021, University of Milana, Milan, Italy

2.Angiogenesi e angiogenesi infiammatoria come bersaglio di terapia e prevenzione in oncologia. Corso di Master in Farmacia e Farmacologia in Oncologia, March 25^h 2021, University of Milana, Milan, Italy

3.Tumor Associated Natural Killer cells (TANKs) in prostate cancer inflammation and angiogenesis. Ph.D. Meeting “Advances in cellular and molecular biology of Prostate cancer”, October 21st, 2019, University of Insubria, Varese, Italy.

4.Angiogenesi e angiogenesi infiammatoria come bersaglio di terapia e prevenzione in oncologia. Corso di Master in Farmacia e Farmacologia in Oncologia, March 25^h 2019, University of Milana, Milan, Italy.

5.Tumor infiltrating (TINKs) and tumor associated (TANKs) Natural Killer cells: new players in tumor angiogenesis orchestration, Seminars within the PhD program in Biotechnology, Biosciences and Surgical Technologies, University of Insubria, meeting “CELLULE PERIFERICHE NEI MECCANISMI DI RISPOSTA IMMUNITARIA E DI PATOGENESI (INFIAMMATORIA E NEOFORMATIVA), POSSIBILE UTILIZZO IN AMBITO DIAGNOSTICO/TERAPEUTICO”, November 8th 2016, University of Insubria, Varese, Italy.

6.“Pro-tumor polarization of Natural Killer cells: mechanisms and mediators”, 2nd INSUBRIA AUTUMN SCHOOL ON NEUROIMMUNE PHARMACOLOGY Repurposing established drugs for novel indications Varese - Italy, November 16th-20th, 2015

7.“Angiogenesis as a target for cancer therapy”, master in Oncological Pharmacology, March 28th2014, University of Milan, Milan, Italy.

Oral Communications and lectures

1.“Natural Killer cells from patients with colorectal cancer are switched towards a decidual-like pro-angiogenic phenotype”,

MACC_10 How to make an optimal blend: Immunotherapy in combination, Cuneo (Italy), November 14th-15th 2017.

2.“Innate immunity driving tumour angiogenesis: the role of Natural Killer cells in non-small cell lung cancer”, 15th International Congress of Immunology, Milan (Italy), august 22nd-27th, 2013

3.“The pro-angiogenic phenotype of Natural Killer cells: a new paradigm of inflammatory infiltrate in tumours”, Workshop SIICA “Angiogenesi: basi molecolari ed implicazioni terapeutiche IV”, CERTOSA DI PONTIGNANO (Siena), Italy, May 13th-15th, 2013

4.“Innate immunity driving tumour angiogenesis: the role of Natural Killer cells in non-small cell lung cancer”, AACR Annual Meeting 2013, Washington DC, April 6th-10th, 2013

5.“The pro-angiogenic phenotype of Natural Killer cells infiltrating squamous cell carcinoma lung cancer”, EACR-22 - from Basic Research to Personalized Cancer Treatment, Barcelona (Spain) 7th-10th, July 2012.

Patents

1. Patent n° 1420805, ITALY, depositato in data 31 ottobre 2013 al n. 102013902203953 concesso in data 29 gennaio 2016 – Brevetto d'invenzione per: USO ANTINFIAMMATORIO DI FITOCOMPLESSI LIQUIDI DA OLIVE

2. Patent n°1420804, ITALY, depositato in data 31 ottobre 2013 al n. 102013902203952 concesso in data 29 gennaio 2016- Brevetto d'invenzione per: USO ANTIANGIOGENICO DI FITOCOMPLESSI LIQUIDI DA OLIVE

Awards

1. AACR Scholar-in-Training Award, AACR Annual meeting 2020, June 22nd-24th, virtual meeting.

2. Fondazione Umberto Veronesi Post-Doctoral Grant, March 2017-February 2018.

3. Fondazione Umberto Veronesi Post-Doctoral fellowship, March 2016-February 2017.

4. NIBIT travel grant, Cancer: Inflammation and Immunity, Santa Caterina in Finalborgo (Finale Ligure, Italy), September 16th-18th, 2015

5. SIICA travel grant award, Workshop SIICA: Angiogenesi: basi molecolari ed implicazioni terapeutiche V, CERTOSA DI PONTIGNANO (Siena), May 25th-27th, 2015

6. AACR Scholar-in-Training Award, AACR Annual meeting 2015, April 18th-22nd, Philadelphia.

7.SIICA Travel grant: 3rd Conference of Translational Medicine on the Pathogenesis and Therapy of Immune-Mediated Diseases, Rozzano (Milan), September 29th- October 1st, 2014.

8.SIC Travel grant: Dangerous Liaisons: translating cancer biology into better patient management - 56^o Congresso Nazionale Società Italiana di Cancerologia, September 11st-13th, 2014.

9.Proffered Paper Award presentation, EACR-22 - from Basic Research to Personalised Cancer Treatment, Barcelona (Spain) July 7th-10th, 2012.

10.FIRC (Fondazione Italiana per la Ricerca sul Cancro) fellowship, January 2012- December 2014.

11.Fellowship for the PhD program in Cellular and Molecular Biology: 2008-2011

I authorize the use of my personal informations, according to the L. 196\03.

Milan, 13/03/2022

A handwritten signature in blue ink, reading "Antonio Bruno". The signature is written in a cursive, flowing style with a large initial 'A'.